Patents & Pipeline

IGC Pharma holds a portfolio of granted and pending patents covering small molecules and pharmaceutical compositions for Alzheimer's disease and other disorders of the central nervous system.

Pipeline

IGC-AD1 is our most advanced candidate, now in Phase 2. Behind it, we are building a portfolio of small molecules — synthetic, semisynthetic, and naturally derived — aimed at multiple unmet needs in Alzheimer's disease.

IGC-AD1

Pre Clinical

Phase 1

Phase 2

Target:

Neuroinflammation, Aβ Plaques, Neurofibrillary Tangles

IGC-AD1 is an oral investigational therapy combining two natural source active ingredients. Intended to help control Alzheimer’s-related agitation by modulating neuroinflammation and reducing oxidative stress.

Modulation of neuroinflammation and reduction of oxidative stress.
Supporting cellular metabolic homeostasis and age-related preservation of central nervous system (CNS) cells.
Modulation of neuronal metabolism and neurotransmission.

Demonstrated safety and tolerability.
Observed reduction in neuropsychiatric symptoms.

Efficacy on agitation in Alzheimer’s.
Efficacy on improvement in cognition due to Alzheimer’s.
Enrollment complete. Topline results expected Q4 2026.

TGR-63

Pre Clinical

Target: Aβ Plaques (Early–Moderate Stage Alzheimer’s)

An NMI small-molecule amyloid modulator that inhibits Aβ aggregation and reduces plaque burden, showing cognitive improvement signals in animal models

Decreased plaque aggregation
Disrupts structure of Aβ peptide
Blood-brain barrier permeability test
Improved memory and learning capacity in mouse models of Alzheimer's

IGC-1C

Pre Clinical

Target: Tau and neurofibrillary tangles

A multifunctional NMI-based, Zn-chelating molecule that inhibits tau LLPS and reduces early tau aggregation.

Prevent tangle formation in vitro.
Decrease Tau oligomer formation

IGC-M3

Pre Clinical

Demonstrated in vitro capacity to decrease plaque and tangle formation
Improved mitochondrial function

IGC-LMP

Pre Clinical

Target: Neuroinflammation, Aβ Plaques, Neurofibrillary Tangles

A prodrug small-molecule family designed to modulate neuroinflammation via disease-relevant inflammatory pathways, supporting the management of Alzheimer's agitation symptoms.

In vitro hydrolysis assay
Bioequivalence assay

Patents
& Pipeline

IGC Pharma holds a portfolio of granted and pending patents covering small molecules and pharmaceutical compositions for Alzheimer's disease and other disorders of the central nervous system.

Pipeline

IGC-AD1 is our most advanced candidate, now in Phase 2. Behind it, we are building a portfolio of small molecules — synthetic, semisynthetic, and naturally derived — aimed at multiple unmet needs in Alzheimer's disease.

Intellectual Property and Patents

Our granted and pending patents protect the compounds and formulations behind every program in our pipeline.

Subscribe to Our Newsletter